Zafgen’s Beloranib No Longer in Development

Zafgen has announced that it is abandoning further development work on its investigational obesity drug beloranib.

The company decided to call it quits for its lead candidate due to the “obstacles, costs and development timelines,” it would incur by continuing development. The drug was placed on clinical hold by the FDA in December 2015.

Zafgen said in a letter to consumers that the benefit/risk ratio of the candidate is “unbalanced” and that its regulatory path forward “is unclear.”